NEW YORK, January 16, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting Cubist Pharmaceuticals Inc. (NASDAQ: CBST), Novavax, Inc. (NASDAQ: NVAX), Exelixis, Inc. (NASDAQ: EXEL), BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), and Foundation Medicine, Inc. (NASDAQ: FMI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Cubist Pharmaceuticals Inc. Research Report
On January 13, 2014, Cubist Pharmaceuticals Inc. (Cubist) released its unaudited Q4 2013 and full-year 2013 revenues. Cubist reported Q4 2013 total net revenue of $299.7 million, up 21.9% YoY, and full-year 2013 total net revenue of $1.1 billion, compared to full-year 2012 net revenue of $926.4 million. The Company stated that CUBICIN® (daptomycin for injection) achieved blockbuster status with full-year 2013 worldwide sales of over $1 billion. Michael Bonney, CEO of Cubist, commented, "With strong revenue growth, two strategic acquisitions, and excellent progress on our pipeline, 2013 was a remarkable year for Cubist. CUBICIN's achievement of blockbuster status is a reminder of the critical need for safe and effective antibiotics around the world and underscores the potential of our pipeline advancing toward commercialization. As we begin 2014, we are more excited than ever by our future growth prospects, and we expect to continue to drive our Building Blocks of Growth through internal discovery and development efforts, as well as through highly focused business development activities." The Company informed that it will host a conference call to discuss complete Q4 2013 and full-year 2013 results on January 23, 2014 at 5:00 p.m. ET, which will be webcast live through its website. The Full Research Report on Cubist Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Novavax, Inc. Research Report
On January 13, 2014, Novavax, Inc. (Novavax) announced that it will continue its partnership with PATH for developing Novavax' RSV (respiratory syncytial virus) vaccine for maternal immunization. Novavax stated that under the amendment, Company will receive from PATH approximately $3.5 million in funding to support the ongoing Phase II dose-confirmatory clinical trial in women of childbearing age, which was commenced in October 2013. The Company added that the companies will also initiate planning activities for clinical development of the vaccine in low-resource countries. Stanley C. Erck, President and CEO of Novavax, said, "PATH, an internationally recognized innovative global health organization, continues to support a key portion of the development expenses for our RSV vaccine candidate. We are gratified by PATH's continued funding of this vaccine development program, which has the potential to dramatically improve pediatric health worldwide." The Full Research Report on Novavax, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Exelixis, Inc. Research Report
On January 13, 2014, Exelixis Inc.'s (Exelixis) stock advanced 6.45%, ending the day at $7.92. Over the previous three trading sessions, shares of Exelixis increased 13.14%, compared to the Nasdaq Composite which declined 1.26% during the same period. The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
BioCryst Pharmaceuticals, Inc. Research Report
On January 13, 2014, BioCryst Pharmaceuticals, Inc.'s (BioCryst) stock advanced 4.27%, ending the day at $10.51. Over the previous three trading sessions, shares of BioCryst increased 11.81%, compared to the Nasdaq Composite which declined 1.26% during the same period. The Full Research Report on BioCryst Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Foundation Medicine, Inc. Research Report
On January 13, 2014, Foundation Medicine, Inc. (Foundation Medicine) released its preliminary unaudited full-year 2013 results and 2014 guidance. Foundation Medicine reported full-year 2013 revenue of $29 million, as compared to $10.6 million for full-year 2012. The Company stated that during Q4 2013, approximately 3,750 FoundationOne™ clinical tests were reported to ordering oncologists, as compared to 2,577 reported in Q3 2013, and over 9,000 clinical tests were reported to ordering oncologists in full-year 2013. Foundation Medicine stated that for 2014, it expects revenues to be in the range of $52 million to $58 million, and to deliver between 22,000 and 25,000 clinical tests. The Company added that Michael J. Pellini, M.D., President and CEO, will present at the 32nd Annual J.P. Morgan Healthcare Conference on January 15, 2014 at 8:00 a.m. PST in San Francisco. The Full Research Report on Foundation Medicine, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner